Ask AI
ES SCLC 1L Therapy

CE / CME

Enhancing Outcomes in Extensive-Stage Small-Cell Lung Cancer With Recent Therapeutic Advancements for First-line Therapy

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Pharmacists: 0.25 contact hour (0.025 CEUs)

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: November 10, 2025

Expiration: May 09, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619-630.
  2. Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.
  3. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7:100408.
  4. Atezolizumab [prescribing information]. South San Francisco, CA: Genetech; 2024.
  5. Kao SC-H, Reck M, Liu SV, et al. 634P Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo). Ann Oncol. 2024;35:S1638-S1638.
  6. Durvalumab [prescribing information]. Wilmington, DE: AstraZeneca; 2024.
  7. Paz-Ares LG, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Presented at: American Society of Clinical Oncology Congress; May 30-June 3, 2025. Abstract 8006.
  8. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: small cell lung cancer. v.1.2026. nccn.org. Accessed October 29, 2025.
  9. Ying, et al. Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies, Cancer Treat Res Commun. 2024;42:100869.
  10. Elijah J, et al. Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting? Support Care Cancer. 2024;32:622.
  11. Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33:853-861.e4.
  12. Rudin CM, et al. First-line pembrolizumab or placebo combined with etoposide and platinum for ES-SCLC: KEYNOTE-604 Long-term follow-up results. Presented at: the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract OA12.06.
  13. Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346-360.e7.
  14. Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025;333:1906-1917.